Even if PFS (Progression-Free Survival) and OS (Overall Survival) in using HER2 molecular-targeted therapies to treat breast cancer increased, addressing therapeutic resistance, especially in the context of metastatic diseases, continues to be a significant challenge in clinical practice [66,85,86]. The gene discussed is ERBB2; the disease is breast carcinoma.